• InterView
• ‘Yuhan expects Leclaza’s FDA approval this year'
• by Kim, Jin-Gu Feb 5, 2024 05:52am

• InterView
• Patent outlook after Forxiga withdrawal in Korea
• by Kim, Jin-Gu Jan 24, 2024 12:37pm

• InterView
• ‘2nd line opt for CMV is limited…should improve access'
• by Son, Hyung-Min Jan 15, 2024 05:36am

• InterView
• Restoring confidence post-Invossa incident was my priority
• by Kim, Jin-Gu Jan 10, 2024 05:42am

• InterView
• ‘RCC treatment should reflect international guidelines’
• by Son, Hyung-Min Jan 9, 2024 05:49am

• InterView
• Targeted cardiomyopathy drug, Camzyos effective in Asians
• by Son, Hyung-Min Dec 19, 2023 11:19am

• InterView
• 'Janssen’s strong in autoimmune diseases for a reason'
• by Eo, Yun-Ho Dec 7, 2023 01:28pm

• InterView
• ‘Leclaza can occupy 50% of mkt if used as combination'
• by Jung, Sae-Im Jul 28, 2023 05:30am

• InterView
• Immunotherapy for early lung cancer was used
• by Jun 29, 2023 05:56am

• InterView
• The use of HTN combi tx in Korea is the highest in the world
• by May 23, 2023 05:53am